PT  - JOURNAL ARTICLE
AU  - Ovale, Antonia Fernandez
AU  - Charles, Cassandra
AU  - Rosenbaum, Janet
AU  - Villalba-Davila, Priscila
AU  - Mora, Mauricio
AU  - Sharma, Shagun
AU  - Lemus, Vivian Vega
AU  - Khandakar, Saema
AU  - Wallach, Thomas
TI  - Older Age and Vaccination Protect Against Transaminase Elevation in Pediatric SARS-CoV2
AID  - 10.1101/2024.04.01.24303996
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.01.24303996
4099  - http://medrxiv.org/content/early/2024/04/01/2024.04.01.24303996.short
4100  - http://medrxiv.org/content/early/2024/04/01/2024.04.01.24303996.full
AB  - Objectives SARS-CoV2 infection is reported to induce transaminase elevations. There are case reports of severe liver injury in adult SARS-CoV2 patients and some have theorized that acute SARS-CoV2 infection may be a driver of severe liver injury in children. While pediatric hepatic injury has previously been described, clear shifts in immunogenic response secondary to prior immune exposure and vaccination since initial reports from 2020 warrant further evaluation. We sought to identify the impact of variant shifts and vaccination on this phenomenon in children.Methods A retrospective, cross-sectional study of pediatric SARS-CoV2 patients seen at two hospital facilities in an urban neighborhood in New York City between March 2020 and March 2022 was conducted via chart review. Data was extracted relating to patient’s demographics, clinical presentation, including the level of care and the laboratory results of comprehensive metabolic panels (CMP).Results 133 pediatric cases were identified as having positive SARS-CoV2 and CMP obtained in the same visit. Patients were predominantly Black (79.2%) and non-Hispanic (87%) with a mean age of 9.2 years. Risk of transaminase elevation was increased in younger patients and patients with higher level of care. BMI was not a risk factor noted for transaminase elevation. Vaccination decreased degree, not incidence, of transaminase elevation but given low rates of vaccination unable to determine significance of protective efficacy.Conclusions Our study has identified a profound increased risk of transaminase elevation in younger patients, the absence of BMI as a correlating factor in our primarily Black patient population, a shift towards non-specific AST elevation with variant windows and a strong signal of vaccine protection.What is KnownSARS-CoV2 can cause Transaminemia, and in rare cases, possible fulminant hepatic injuryPediatric SARS-CoV2 infections are statistically milder than adult.SARS-Cov2 case severity and complications like multisystem inflammatory syndrome in children have declined over timeWhat is NewWith population immunity and variant shifts transaminase elevations increasingly may not be of hepatic originRisk of transaminase elevation is substantially higher in younger patients, and decreases with ageVaccines are protective against degree of transaminase elevation, and likely against incidence of transaminase elevation, although further study is needed.Article Summary Cross sectional study of an urban pediatric population demonstrates SARS-CoV2 transaminase elevation linked with younger age, unvaccinated status, and higher level of care.Competing Interest StatementThe authors have declared no competing interest.Funding Statementunfunded study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval granted by SUNY Downstate IRB and the kings County Hospital Center STAR CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available on request.(AST)Aspartate Aminotransferase(AST)Alanine Aminotransferase(SES)Socioeconomic Status